Search Results
10
Everything
Search Filters
Organization
Septerna, Inc.
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
March 27, 2025 08:00 ET
|
Septerna, Inc.
Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for...
Septerna to Present at TD Cowen 45th Annual Health Care Conference
February 26, 2025 08:00 ET
|
Septerna, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today...
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
February 18, 2025 08:00 ET
|
Septerna, Inc.
Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures...
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer
January 06, 2025 07:00 ET
|
Septerna, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug...
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 18, 2024 08:00 ET
|
Septerna, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey...
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 20, 2024 07:00 ET
|
Septerna, Inc.
Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small...
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
October 30, 2024 16:41 ET
|
Septerna, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral...
Septerna Prices Upsized Initial Public Offering
October 24, 2024 21:47 ET
|
Septerna, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral...